Breaking News Instant updates and real-time market news.

KDMN

Kadmon

$6.04

-0.07 (-1.15%)

14:26
11/20/16
11/20
14:26
11/20/16
14:26

Kadmon reports new data on tesevatinib in kidney cyst patients

Kadmon announced additional data from its ongoing Phase 2a clinical study demonstrating the safety of tesevatinib for the treatment of autosomal dominant polycystic kidney disease. The data will be presented at the American Society of Nephrology Kidney Week. "Recent findings from Kadmon's ongoing Phase 2a study in patients with ADPKD have demonstrated that tesevatinib is well tolerated and have also identified tesevatinib 50 mg once daily as the optimal dose to treat ADPKD. New data reported in the poster indicate that tesevatinib is a new member of a group of drugs known as MATE 1/2-K transporter inhibitors, such as cimetidine, which mildly increase levels of serum creatinine. Normally, an increase in serum creatinine can be used to indicate kidney damage, but in the case of MATE 1/2-K inhibitors, these serum creatinine increases occur without clinically meaningful alterations in renal function. Specifically, new data demonstrated that serum creatinine levels in tesevatinib patients increased by 10%-14% during the first 28 days of treatment and reversed upon treatment discontinuation. Importantly, levels of cystatin C, another measure of renal function, were relatively unchanged during the same period. In vitro studies demonstrated that tesevatinib potently inhibits MATE1/2-K transporters at tesevatinib concentrations achieved with the 50 mg QD dose. Therefore, MATE inhibition by tesevatinib may explain mild serum creatinine increases associated with tesevatinib treatment," the company reported. "Kadmon has had discussions with the FDA to develop innovative methods to demonstrate drug safety and efficacy in PKD, a major unmet medical need. These discussions will have important implications for clinical trial designs for tesevatinib as well as other therapies in development for renal diseases, especially MATE inhibitors," noted CMO John Ryan.

  • 29

    Nov

KDMN Kadmon
$6.04

-0.07 (-1.15%)

08/22/16
SBSH
08/22/16
INITIATION
Target $12
SBSH
Neutral
Kadmon initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas initiated Kadmon with a Neutral and $12 price target saying most of its programs are risky with limited clinical data, and the ongoing trials are small proof of concept trials which could limit the upside.
08/22/16
HCWC
08/22/16
INITIATION
Target $25
HCWC
Buy
Kadmon initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Kadmon with a Buy and $25 price target.
08/22/16
08/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AK Steel (AKS) initiated with a Neutral at Citi and a Buy at Rosenblatt. 2. U.S. Steel (X) and Steel Dynamics (STLD) were initiated with a Buy at Citi while the firm initiated Nucor (NUE) and Commercial Metals (CMC) with a Neutral. 3. Pinnacle Entertainment (PNK) initiated with a Buy at BofA/Merrill. 4. Ferrellgas Partners LP (FGP) initiated with a Neutral at Piper Jaffray. 5. Kadmon (KDMN) initiated with an Outperform at JMP Securities, with a Neutral at Citi, and with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/16
JMPS
09/15/16
NO CHANGE
JMPS
Kadmon has positive read through from Allergan deal, says JMP Securities
JMP Securities analyst Michael King says that Allergan's (AGN) acquisition of Vitae Pharmaceuticals (VTAE) bodes well for Kadmon's (KDMN) ROCK inhibitor KD025 for patients with psoriasis. The analyst says that the main driver for the Vitae deal was its oral RORyt inhibitor VTP-43742 which could become a psoriasis treatment. There are "mechanistic similarities" between Vitae's drug and Kadmon's psoriasis drug candidate KD025, King wrote. He reiterates a $16 price target and Outperform rating on Kadmon.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.57

0.03 (0.05%)

19:34
02/22/17
02/22
19:34
02/22/17
19:34
Hot Stocks
Market researcher: Starbucks consumer perception dips after refugee hiring news »

Market researcher YouGov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

LB

Labarge

$58.13

0.43 (0.75%)

19:33
02/22/17
02/22
19:33
02/22/17
19:33
Hot Stocks
L Brands sees Q1 comps down high-single to low-double digits »

Sees Q1 Go-Forwards comps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

19:32
02/22/17
02/22
19:32
02/22/17
19:32
Hot Stocks
L Brands sees FY17 comps down low-single digits »

Sees FY17 Go-Forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

F

Ford

$12.67

-0.02 (-0.16%)

19:30
02/22/17
02/22
19:30
02/22/17
19:30
Conference/Events
Ford to host sales conference call »

Ford U.S. Sales Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

GTLS

Chart Industries

$38.51

-1.21 (-3.05%)

19:27
02/22/17
02/22
19:27
02/22/17
19:27
Hot Stocks
Chart Industries CEO Samuel Thomas named executive chairman »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$273.51

-3.88 (-1.40%)

19:24
02/22/17
02/22
19:24
02/22/17
19:24
Periodicals
SolarCity leased with risky homeowners, has ties to foreclosure cases, NYT says »

In "dozens of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PRU

Prudential

$110.50

-0.72 (-0.65%)

, WFC

Wells Fargo

$58.36

0.11 (0.19%)

19:16
02/22/17
02/22
19:16
02/22/17
19:16
Hot Stocks
Prudential says could seek compensation from Wells Fargo over MyTerm products »

Prudential (PRU) stated…

PRU

Prudential

$110.50

-0.72 (-0.65%)

WFC

Wells Fargo

$58.36

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 13

    Apr

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PSA

Public Storage

$226.24

-1.49 (-0.65%)

19:15
02/22/17
02/22
19:15
02/22/17
19:15
Earnings
Public Storage reports Q4 core FFO $2.65, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

19:10
02/22/17
02/22
19:10
02/22/17
19:10
Periodicals
Credit Suisse probed for potentially aiding tax evasion, WSJ says »

Less than three years…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

LZB

La-Z-Boy

$28.40

-1.05 (-3.57%)

19:09
02/22/17
02/22
19:09
02/22/17
19:09
Downgrade
La-Z-Boy rating change  »

La-Z-Boy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

19:06
02/22/17
02/22
19:06
02/22/17
19:06
Syndicate
Cloud Peak 13.5M share Spot Secondary priced at $5.10 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SNAP

Snap Inc

18:47
02/22/17
02/22
18:47
02/22/17
18:47
Periodicals
Snap Inc nears $200M ad deal, NY Post says »

Snap Inc is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SBLK

Star Bulk Carriers

$9.59

0.29 (3.12%)

18:40
02/22/17
02/22
18:40
02/22/17
18:40
Earnings
Star Bulk Carriers reports Q4 EPS (29c), consensus (28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 22

    Mar

C

Citi

$60.62

0.07 (0.12%)

18:35
02/22/17
02/22
18:35
02/22/17
18:35
Periodicals
Citi forms regulatory affairs team in D.C., Bloomberg says »

Citi is forming a global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:34
02/22/17
02/22
18:34
02/22/17
18:34
Earnings
PRA Health sees FY17 EPS $3.08-$3.18, consensus $2.96 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

, ATH

Athene Holding

$51.45

0.38 (0.74%)

18:32
02/22/17
02/22
18:32
02/22/17
18:32
Periodicals
Fidelity & Guaranty Life revives sale process, Insurance Insider says »

Fidelity & Guaranty…

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

ATH

Athene Holding

$51.45

0.38 (0.74%)

APO

Apollo Global

$22.25

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:31
02/22/17
02/22
18:31
02/22/17
18:31
Earnings
PRA Health sees Q1 EPS 57c-62c, consensus 67c »

Sees Q1 service revenues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NBR

Nabors Industries

$15.44

0.01 (0.06%)

18:30
02/22/17
02/22
18:30
02/22/17
18:30
Earnings
Nabors Industries reports Q4 EPS ($1.17) with items »

Q4 EPS includes 87c in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:28
02/22/17
02/22
18:28
02/22/17
18:28
Earnings
AxoGen reiterates FY17 revenue growth view of at least 40% »

Management reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:26
02/22/17
02/22
18:26
02/22/17
18:26
Earnings
AxoGen reports Q4 EPS (10c), consensus (9c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

18:26
02/22/17
02/22
18:26
02/22/17
18:26
Earnings
Genesis Healthcare sees FY17 revenue $5.4B-$5.6B, consensus $5.64B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

URRE

Uranium Resources

$1.91

-0.06 (-3.05%)

18:25
02/22/17
02/22
18:25
02/22/17
18:25
Hot Stocks
Uranium Resources reports favorable lithium concentrations at Columbus Basin »

Uranium Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

18:24
02/22/17
02/22
18:24
02/22/17
18:24
Earnings
Genesis Healthcare reports Q4 revenue $1.4B, consensus $1.4B »

Reports Q4 net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MCRI

Monarch Casino

$23.98

-0.22 (-0.91%)

18:22
02/22/17
02/22
18:22
02/22/17
18:22
Earnings
Monarch Casino reports Q4 EPS 36c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMX

CombiMatrix

$4.10

-0.1 (-2.38%)

, UCTT

Ultra Clean

$12.58

0.2 (1.62%)

18:22
02/22/17
02/22
18:22
02/22/17
18:22
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

CBMX

CombiMatrix

$4.10

-0.1 (-2.38%)

UCTT

Ultra Clean

$12.58

0.2 (1.62%)

SQ

Square

$15.04

0.41 (2.80%)

CTRP

Ctrip.com

$47.59

0.53 (1.13%)

TSLA

Tesla

$273.51

-3.88 (-1.40%)

BLCM

Bellicum Pharmaceuticals

$12.79

-0.6 (-4.48%)

LB

Labarge

$58.13

0.43 (0.75%)

TSRA

Tessera

$44.65

-0.2 (-0.45%)

ARRS

ARRIS

$30.70

0.75 (2.50%)

JACK

Jack in the Box

$103.60

-3.77 (-3.51%)

SAM

Boston Beer

$166.85

-1.9 (-1.13%)

ELGX

Endologix

$6.53

0.04 (0.62%)

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

FMI

Foundation Medicine

$23.85

-0.6 (-2.45%)

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

NGD

New Gold

$3.04

-0.08 (-2.56%)

NVDA

NVIDIA

$110.76

-0.31 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 14

    Mar

  • 16

    Mar

  • 16

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 23

    Feb

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.